Evidence map›Paper›PMID 38254122›Full record

ReviewOrphanet journal of rare diseases2024

Developing a community-led rare disease ELSI research agenda.

Courtney Berrios, Macy McBeth, Andrea Bradley-Ewing, Nikolaus Schuetz, Annette Campbell, Zohreh Talebizadeh, Jeremy R Garrett, Tamara Falicov, Francisco Martinez, Rare Voices Advisory Group and 1 more

Abstract readReview
In one paragraph

Review in Orphanet journal of rare diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Downstream Exclusion in Rural Rare Disease Precision Medicine Research.The American journal of bioethics : AJOB · 2024
    Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Courtney BerriosGenomic Medicine Center, Children's Mercy Kansas City, Kansas City, MO, USA. cdberrios@cmh.edu.ORCID 0000-0001-5170-070X
Macy McBethGenomic Medicine Center, Children's Mercy Kansas City, Kansas City, MO, USA.
Andrea Bradley-EwingHealth Services and Outcomes Research, Children's Mercy Kansas City, Kansas City, MO, USA.
Nikolaus SchuetzHealth Services and Outcomes Research, Children's Mercy Kansas City, Kansas City, MO, USA.
Annette CampbellRareKC, Overland Park, KS, USA.
Zohreh TalebizadehAmerican College of Medical Genetics and Genomics, Bethesda, MD, USA.
Jeremy R GarrettUniversity of Missouri Kansas City, Kansas City, MO, USA.
Tamara FalicovUniversity of Missouri Kansas City, Kansas City, MO, USA.
Francisco MartinezOffice of Equity and Diversity, Children's Mercy Kansas City, Kansas City, MO, USA.
Rare Voices Advisory Group
Emily A HurleyUniversity of Missouri Kansas City, Kansas City, MO, USA.

Funding

Patient-Centered Outcomes Research Institute 20996-CMH
6 · The paper itself

Abstract

backgroundResearch priorities are best defined through engagement with communities who will be impacted by the research and have lived experience of the topics to be studied. We aimed to establish a pediatric rare disease community stakeholder group and empower them in (1) eliciting perspectives from affected families in the wider region and (2) synthesizing collective ideas into a research agenda focused on shared ethical, legal, and social implications (ELSI) across rare disease.

methodsThis two-year project utilized a community-centered approach to engage rare disease community members as equal partners in developing a research agenda for ELSI in rare disease. We established "Rare Voices" (RV), a 22-member stakeholder group of patients, parents, clinicians and researchers. Following capacity-building trainings, RV designed and conducted listening sessions with teen patients and parents of children with rare diseases to explore challenges, positive experiences, and ethical concerns. Listening session findings were synthesized and contextualized into research topics, which RV members further refined and prioritized. We used established measures to assess RV member engagement and satisfaction.

resultsFrom 14 listening sessions with parents (n = 52) and teen patients (n = 13), RV identified eight core research topics as most important for future rare disease research: coordinating care, communication, accessing resources and care, impact on family unit, community and support in society, mental health and identity, ethical aspects of care, and uncertainty. RV members were highly engaged throughout the two-year project and reported high levels of satisfaction with the experience and research agenda.

conclusionsThrough capacity-building and authentic engagement, this project resulted in a community-led rare disease research agenda to guide future rare disease ELSI research that aligns with patients' and families' priorities. An environment of equal partnership and respect created a space for mutual learning where community members were empowered to shape the research agenda based on their collective experiences. The agenda recognizes the shared psychosocial and healthcare experiences of rare disease and offers practical areas of research to address patient and family needs.

Indexed as

Mental HealthRare DiseasesAdolescentChildHumansParentsCommunity engagementELSIRare diseaseResearch agenda

Identifiers

PMID38254122
PMCPMC10801933

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.